Patti E. Gravitt
Research Subjects
Research Interests
Patti E. Gravitt has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Keerti V. Shah
Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
5 shared publicationsGayatri Ramakrishna
Center for DNA Fingerprinting and Diagnostics, Hyderabad, India
4 shared publications- Michelle I. Silver
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, E6148, Baltimore, MD 21205
4 shared publications Proma Paul
Departments of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
4 shared publicationsAllan Hildesheim
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852-7234
3 shared publicationsBrigitte M. Ronnett
Departments of Pathology and Gynecology and Obstetrics, The Johns Hopkins University School of Medicine and Hospital, Baltimore, Maryland, United States of America
3 shared publications
Latest Publications
- 1 October 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (1) , 201-202
Failure to Correct for Hysterectomy Prevalence Underestimates the Racial Disparity in US Cervical Cancer Mortality Rates
- 1 October 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (1) , 201-202
Failure to Correct for Hysterectomy Prevalence Underestimates the Racial Disparity in US Cervical Cancer Mortality Rates
- 1 August 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 60 (4) , 414-417
Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic
- 1 August 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 60 (4) , 414-417
Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic
- Open Access
- 15 January 2013
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 207 (2) , 272-280
A Cohort Effect of the Sexual Revolution May Be Masking an Increase in Human Papillomavirus Detection at Menopause in the United States
Background. Cohort effects, new sex partnerships, and human papillomavirus (HPV) reactivation have been posited as explanations for the bimodal age-specific HPV prevalence observed in some populations; no studies have systematically evaluated the reasons for the lack of a second peak in the United States.
- 15 January 2013
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 207 (2) , 272-280
Open AccessA Cohort Effect of the Sexual Revolution May Be Masking an Increase in Human Papillomavirus Detection at Menopause in the United States
Background. Cohort effects, new sex partnerships, and human papillomavirus (HPV) reactivation have been posited as explanations for the bimodal age-specific HPV prevalence observed in some populations; no studies have systematically evaluated the reasons for the lack of a second peak in the United States.
- Open Access
- 7 January 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 5
Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta
There are no data available on human papillomavirus (HPV) infections in women living in the Mississippi Delta, where cervical cancer incidence and mortality among African American women is among the highest in the United States. The aim of this analysis was to report the age-specific prevalence of HPV in this population.
- 7 January 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 5
Open AccessHuman papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta
There are no data available on human papillomavirus (HPV) infections in women living in the Mississippi Delta, where cervical cancer incidence and mortality among African American women is among the highest in the United States. The aim of this analysis was to report the age-specific prevalence of HPV in this population.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 303
Concordant Oral-Genital HPV Infection in South Africa Couples: Evidence for Transmission
Objective: Cervical cancer is a leading cause of cancer mortality in South Africa. However, little is known about oral HPV infection in high HIV seroprevalence settings. Method: 34 adult heterosexual couples attending an HIV testing center in Soweto, South Africa were enrolled. Each participant provided an oral rinse sample and genital swab, which were tested for 37 types of HPV DNA, and completed a risk behavior survey. Results: Median age was 31 years and 9% (3/34) of men and 29% (10/34) of women enrolled tested HIV-positive; median CD4 count was 437cells/mm3. Oral HPV prevalence was similar in women and men (12% vs 18%, p=0.48), and was non-significantly higher in HIV-infected vs. HIV-uninfected (23% vs. 13%, p=0.34) subjects. Most men (82%) and women (84%) reported ever performing oral sex. Median number of lifetime sexual partners was “2-5”while median number of lifetime oral sex partners was 1. Oncogenic HPV subtypes were detected in 4% of oral, 26% of penile, and 74% of vaginal samples, including HPV16 in 1%, 12%, and 21% of these samples respectively. Genital HPV prevalence was significantly higher than oral HPV prevalence (75% vs. 15%, p=
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 303
Open AccessConcordant Oral-Genital HPV Infection in South Africa Couples: Evidence for Transmission
Objective: Cervical cancer is a leading cause of cancer mortality in South Africa. However, little is known about oral HPV infection in high HIV seroprevalence settings. Method: 34 adult heterosexual couples attending an HIV testing center in Soweto, South Africa were enrolled. Each participant provided an oral rinse sample and genital swab, which were tested for 37 types of HPV DNA, and completed a risk behavior survey. Results: Median age was 31 years and 9% (3/34) of men and 29% (10/34) of women enrolled tested HIV-positive; median CD4 count was 437cells/mm3. Oral HPV prevalence was similar in women and men (12% vs 18%, p=0.48), and was non-significantly higher in HIV-infected vs. HIV-uninfected (23% vs. 13%, p=0.34) subjects. Most men (82%) and women (84%) reported ever performing oral sex. Median number of lifetime sexual partners was “2-5”while median number of lifetime oral sex partners was 1. Oncogenic HPV subtypes were detected in 4% of oral, 26% of penile, and 74% of vaginal samples, including HPV16 in 1%, 12%, and 21% of these samples respectively. Genital HPV prevalence was significantly higher than oral HPV prevalence (75% vs. 15%, p=
- Open Access
- 28 December 2012
- Published by Bentham Science Publishers Ltd. in The Open Virology Journal
- Vol. 6 (1) , 198-203
Evidence and Impact of Human Papillomavirus Latency
At present, there is no consensus in the scientific community regarding the ability for human papillomavirus (HPV) infections to establish latency. Based on animal studies, a model of papillomavirus latency has been proposed in which papillomaviruses can be retained in the basal epithelial stem cell pool as latent infections and periodically induced to reactivate when the stem cell divides and one daughter cell is committed to terminal differentiation and induction of the viral life cycle. Tissue resident memory T-cells are hypothesized to control these periodic reactivation episodes and thus limit their duration. In this paper, evidence from human studies consistent with this model of papillomavirus latency is reviewed. Given the strong circumstantial evidence supporting a natural history of HPV infection which includes a immunologically controlled latent state, the longer term implications of HPV latency on a highly infected and aging population may warrant a more serious evaluation.
- 28 December 2012
- Published by Bentham Science Publishers Ltd. in The Open Virology Journal
- Vol. 6 (1) , 198-203
Open AccessEvidence and Impact of Human Papillomavirus Latency
At present, there is no consensus in the scientific community regarding the ability for human papillomavirus (HPV) infections to establish latency. Based on animal studies, a model of papillomavirus latency has been proposed in which papillomaviruses can be retained in the basal epithelial stem cell pool as latent infections and periodically induced to reactivate when the stem cell divides and one daughter cell is committed to terminal differentiation and induction of the viral life cycle. Tissue resident memory T-cells are hypothesized to control these periodic reactivation episodes and thus limit their duration. In this paper, evidence from human studies consistent with this model of papillomavirus latency is reviewed. Given the strong circumstantial evidence supporting a natural history of HPV infection which includes a immunologically controlled latent state, the longer term implications of HPV latency on a highly infected and aging population may warrant a more serious evaluation.
- 1 August 2012
- Published by Elsevier in Journal of Immunological Methods
- Vol. 382 (1-2) , 211-215
Comparison of normalization methods for measuring immune markers in cervical secretion specimens
- 1 August 2012
- Published by Elsevier in Journal of Immunological Methods
- Vol. 382 (1-2) , 211-215
Comparison of normalization methods for measuring immune markers in cervical secretion specimens
- Open Access
- 29 September 2011
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 204 (10) , 1505-1513
Combined Oral Contraceptive Use Increases HPV Persistence but Not New HPV Detection in a Cohort of Women From Thailand
Background. Women diagnosed with cervical cancer report longer duration and more recent use of combined oral contraceptives (COCs). It is unclear how COC use impacts risk of cervical carcinogenesis. Methods. We estimated the risk of new human papillomavirus (HPV) DNA detection and persistence among 1135 human immunodeficiency virus (HIV)–negative women aged 20–37 years from Thailand who were followed for 18 months at 6-month intervals. Type-specific HPV DNA, demographic information, hormonal contraceptive use, sexual behavior, genital tract coinfection, and Papanicolaou test results were assessed at baseline and each follow-up. Results. Women who reported current COC use during follow-up were less likely to clear HPV infection compared with nonusers, independent of sexual behavior, and Papanicolaou test diagnosis (AHR: 0.67 [95% CI: .49–.93]). Similar associations were not observed among women reporting current use of depomedroxyprogesterone acetate (DMPA). Neither COC nor DMPA use was significantly associated with new HPV DNA detection. Conclusions. These data do not support the hypothesis that contraceptive use is associated with cervical cancer risk via increased risk of HPV acquisition. The increased risk of HPV persistence observed among current COC users suggests a possible influence of female sex hormones on host response to HPV infection.
- 29 September 2011
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 204 (10) , 1505-1513
Open AccessCombined Oral Contraceptive Use Increases HPV Persistence but Not New HPV Detection in a Cohort of Women From Thailand
Background. Women diagnosed with cervical cancer report longer duration and more recent use of combined oral contraceptives (COCs). It is unclear how COC use impacts risk of cervical carcinogenesis. Methods. We estimated the risk of new human papillomavirus (HPV) DNA detection and persistence among 1135 human immunodeficiency virus (HIV)–negative women aged 20–37 years from Thailand who were followed for 18 months at 6-month intervals. Type-specific HPV DNA, demographic information, hormonal contraceptive use, sexual behavior, genital tract coinfection, and Papanicolaou test results were assessed at baseline and each follow-up. Results. Women who reported current COC use during follow-up were less likely to clear HPV infection compared with nonusers, independent of sexual behavior, and Papanicolaou test diagnosis (AHR: 0.67 [95% CI: .49–.93]). Similar associations were not observed among women reporting current use of depomedroxyprogesterone acetate (DMPA). Neither COC nor DMPA use was significantly associated with new HPV DNA detection. Conclusions. These data do not support the hypothesis that contraceptive use is associated with cervical cancer risk via increased risk of HPV acquisition. The increased risk of HPV persistence observed among current COC users suggests a possible influence of female sex hormones on host response to HPV infection.